Study of Biomarkers of Airway Inflammation (0000-128)

Model scores of the 29,894 trials active now.

Model score 3% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2009-09-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: subject hascelleffectsmajorsurgery
  Phrases that lowered it: healthynasalvolunteersscreeninginhaled
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Design: crossover (lowers risk) · Design
• Sponsor's past termination rate: 16.1% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Drug's FAERS reports marked serious: 59.1% (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 6.9% (lowers risk) · Drug's FDA history
• Blinding: double (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: diagnostic (lowers risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports in the prior 12 months: 5676 (lowers risk) · Drug's FDA history
• Number of arms: 3 (lowers risk) · Design
• Maximum age: 50 (lowers risk) · Who can join
• Drugs with FDA adverse-event history: 3 (raises risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area
• Sponsor's past trials: 510 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study To Determine Effects Of Fluticasone Propionate On Sputum Neutrophils After Inhaled Lipopolysaccharide Challenge In Volunteers NCT01364519 · started 2011 · scored riskier than 4% of active trials completed
• Induced Sputum Study (0000-065) NCT00623714 · started 2008 · scored riskier than 6% of active trials completed
• Single Dose Lipopolysaccharide (LPS) Study In Healthy Volunteers NCT01314885 · started 2011 · scored riskier than 3% of active trials completed
• A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung Function NCT01287065 · started 2010 · scored riskier than 3% of active trials completed
• Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry. NCT01498679 · started 2012 · scored riskier than 7% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.